Skip to content
OpenCapital
Get started

Gilead Sciences GILD Total Cell Therapy — Total revenues

Other product segments

Biktarvy
$3.36B+6.7%
Descovy
$807M+37.7%
Trodelvy
$402M+37.2%
Yescarta
$332M-14.0%
Sofosbuvir/Velpatasvir
$283M-18.2%
Genvoya
$264M-27.5%
Vemlidy
$237M-6.0%
Odefsey
$221M-21.4%
Yeztugo
$166M—
Veklury
$144M-52.3%
AmBisome
$138M-0.7%
Symtuza - Revenue share
$138M+21.1%
Livdelzi
$133M+233%
Other Liver Disease
$114M-5.8%
Tecartus
$75M-3.8%
Other HIV
$73M-19.8%
Other
$58M-17.1%
Royalty, contract and other revenues
$14M-74.1%

Similar metrics at other companies

10x Genomics, Inc. logo
TXGSingle Cell — Total Revenue
$90.8M-2.4%
Mirion Technologies logo
MIRCancer care — Total revenues
$55.3M+8.4%
Biogen logo
BIIBRevenue from anti-CD20 therapeutic programs — Total Revenue
$419.1M+10.8%
BioMarin Pharmaceuticals logo
BMRNROCTAVIAN — Total revenues
$2.64M-74.9%
Amneal Pharmaceuticals, Inc. logo
AMRXSubtotal therapeutic classes — Net revenue
$133.27M+23.1%
Vertex Pharmaceuticals logo
VRTXTotal CF product revenues, net — Total revenues
$2.92B+6.2%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$153.66B+23.8%
Enterprise value$168.2B+19.7%
P/E16.7×-4.1×
P/S5.2×+0.8×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's total cell therapy — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's total cell therapy — total revenues?
Gilead Sciences (GILD) reported total cell therapy — total revenues of $407M in Q1 2026.
How has Gilead Sciences's total cell therapy — total revenues changed year-over-year?
Gilead Sciences's total cell therapy — total revenues decreased by 12.3% year-over-year, from $464M to $407M.
What is the long-term trend for Gilead Sciences's total cell therapy — total revenues?
Over 4 years (2021 to 2025), Gilead Sciences's total cell therapy — total revenues has grown at a 20.5% compound annual growth rate (CAGR), from $871M to $1.84B.
What does total cell therapy — total revenues mean?
This metric represents the total gross revenue generated from the sale of cell therapy products within the company's oncology and specialized treatment portfolio. It captures the market adoption and commercial performance of advanced therapeutic platforms, such as CAR-T cell therapies, used in the treatment of hematological malignancies. This figure serves as a key indicator of the company's success in scaling high-complexity, personalized medicine offerings.